Table 1_Immune checkpoint inhibitor therapy in advanced cancer: clinical association of irAEs type, inflammatory markers and efficacy.docx
Background<p>Immune checkpoint inhibitors (ICIs) improve survival in advanced cancers but are associated with immune-related adverse events (irAEs), whose prognostic impact remains debated. The role of systemic inflammatory biomarkers is also not fully defined.</p>Methods<p>This re...
में बचाया:
| मुख्य लेखक: | |
|---|---|
| अन्य लेखक: | , , , , , , |
| प्रकाशित: |
2025
|
| विषय: | |
| टैग: |
टैग जोड़ें
कोई टैग नहीं, इस रिकॉर्ड को टैग करने वाले पहले व्यक्ति बनें!
|
| _version_ | 1849927624762064896 |
|---|---|
| author | Mengying Qian (2541466) |
| author2 | Ping Ma (15010) Yu Zhao (104852) Hao Jiang (95017) LiYang Gao (22686257) Gaoyang Lin (8495742) Difan Duan (22686260) Jinmin Guo (8665254) |
| author2_role | author author author author author author author |
| author_facet | Mengying Qian (2541466) Ping Ma (15010) Yu Zhao (104852) Hao Jiang (95017) LiYang Gao (22686257) Gaoyang Lin (8495742) Difan Duan (22686260) Jinmin Guo (8665254) |
| author_role | author |
| dc.creator.none.fl_str_mv | Mengying Qian (2541466) Ping Ma (15010) Yu Zhao (104852) Hao Jiang (95017) LiYang Gao (22686257) Gaoyang Lin (8495742) Difan Duan (22686260) Jinmin Guo (8665254) |
| dc.date.none.fl_str_mv | 2025-11-26T05:14:32Z |
| dc.identifier.none.fl_str_mv | 10.3389/fimmu.2025.1662333.s001 |
| dc.relation.none.fl_str_mv | https://figshare.com/articles/dataset/Table_1_Immune_checkpoint_inhibitor_therapy_in_advanced_cancer_clinical_association_of_irAEs_type_inflammatory_markers_and_efficacy_docx/30717500 |
| dc.rights.none.fl_str_mv | CC BY 4.0 info:eu-repo/semantics/openAccess |
| dc.subject.none.fl_str_mv | Genetic Immunology immune checkpoint inhibitors inflammatory biomarkers immune-related adverse events overall survival meta-analysis |
| dc.title.none.fl_str_mv | Table 1_Immune checkpoint inhibitor therapy in advanced cancer: clinical association of irAEs type, inflammatory markers and efficacy.docx |
| dc.type.none.fl_str_mv | Dataset info:eu-repo/semantics/publishedVersion dataset |
| description | Background<p>Immune checkpoint inhibitors (ICIs) improve survival in advanced cancers but are associated with immune-related adverse events (irAEs), whose prognostic impact remains debated. The role of systemic inflammatory biomarkers is also not fully defined.</p>Methods<p>This research merged a comprehensive systematic review and meta-analysis of 38 studies involving 55,966 participants with a multicenter retrospective cohort study of 870 patients receiving ICI therapy. The aim of this study was to examine the association between irAE characteristics and severity, and baseline inflammatory indicators (NLR, dNLR and PLR), with clinical outcomes, particularly survival (OS) and disease progression survival (PFS). The data were analyzed through time-dependent cox model and meta-analysis.</p>Results<p>Among 870 immunotherapy patients, 32.4% developed irAEs, predominantly grade 1-2 (83.9%). Severe irAEs (grade >2) significantly increased mortality (OS HR = 1.93). Organ-specific analysis identified endocrine (HR = 0.938, p < 0.001) and skin toxicity (HR = 0.763, p<0.001) as independent protective factors for OS, while hepatic (HR = 1.602, p=0.031) and cardiac toxicity (HR = 1.181, p=0.017) were risk factors. Elevated baseline inflammatory markers—MLR >0.47 (HR = 3.37), NLR >3.45 (HR = 2.24), and PLR >186.98 (HR = 2.10)—also predicted poorer OS. A meta-analysis confirmed that low-grade irAEs (grade ≤2) conferred significant survival benefit (OS HR = 0.54), particularly skin and endocrine toxicities. These findings support irAEs as biomarkers of immunotherapy response, with prognostic relevance shaped by severity and organ involvement.</p>Conclusions<p>The prognosis of irAEs depends on organ involvement and severity. Endocrine and skin toxicities confer survival benefits, while severe, hepatic, and cardiac events pose significant risks. Inflammatory markers predict survival but not irAE onset.</p> |
| eu_rights_str_mv | openAccess |
| id | Manara_be18a20680f2f50f949624f7fa046ac1 |
| identifier_str_mv | 10.3389/fimmu.2025.1662333.s001 |
| network_acronym_str | Manara |
| network_name_str | ManaraRepo |
| oai_identifier_str | oai:figshare.com:article/30717500 |
| publishDate | 2025 |
| repository.mail.fl_str_mv | |
| repository.name.fl_str_mv | |
| repository_id_str | |
| rights_invalid_str_mv | CC BY 4.0 |
| spelling | Table 1_Immune checkpoint inhibitor therapy in advanced cancer: clinical association of irAEs type, inflammatory markers and efficacy.docxMengying Qian (2541466)Ping Ma (15010)Yu Zhao (104852)Hao Jiang (95017)LiYang Gao (22686257)Gaoyang Lin (8495742)Difan Duan (22686260)Jinmin Guo (8665254)Genetic Immunologyimmune checkpoint inhibitorsinflammatory biomarkersimmune-related adverse eventsoverall survivalmeta-analysisBackground<p>Immune checkpoint inhibitors (ICIs) improve survival in advanced cancers but are associated with immune-related adverse events (irAEs), whose prognostic impact remains debated. The role of systemic inflammatory biomarkers is also not fully defined.</p>Methods<p>This research merged a comprehensive systematic review and meta-analysis of 38 studies involving 55,966 participants with a multicenter retrospective cohort study of 870 patients receiving ICI therapy. The aim of this study was to examine the association between irAE characteristics and severity, and baseline inflammatory indicators (NLR, dNLR and PLR), with clinical outcomes, particularly survival (OS) and disease progression survival (PFS). The data were analyzed through time-dependent cox model and meta-analysis.</p>Results<p>Among 870 immunotherapy patients, 32.4% developed irAEs, predominantly grade 1-2 (83.9%). Severe irAEs (grade >2) significantly increased mortality (OS HR = 1.93). Organ-specific analysis identified endocrine (HR = 0.938, p < 0.001) and skin toxicity (HR = 0.763, p<0.001) as independent protective factors for OS, while hepatic (HR = 1.602, p=0.031) and cardiac toxicity (HR = 1.181, p=0.017) were risk factors. Elevated baseline inflammatory markers—MLR >0.47 (HR = 3.37), NLR >3.45 (HR = 2.24), and PLR >186.98 (HR = 2.10)—also predicted poorer OS. A meta-analysis confirmed that low-grade irAEs (grade ≤2) conferred significant survival benefit (OS HR = 0.54), particularly skin and endocrine toxicities. These findings support irAEs as biomarkers of immunotherapy response, with prognostic relevance shaped by severity and organ involvement.</p>Conclusions<p>The prognosis of irAEs depends on organ involvement and severity. Endocrine and skin toxicities confer survival benefits, while severe, hepatic, and cardiac events pose significant risks. Inflammatory markers predict survival but not irAE onset.</p>2025-11-26T05:14:32ZDatasetinfo:eu-repo/semantics/publishedVersiondataset10.3389/fimmu.2025.1662333.s001https://figshare.com/articles/dataset/Table_1_Immune_checkpoint_inhibitor_therapy_in_advanced_cancer_clinical_association_of_irAEs_type_inflammatory_markers_and_efficacy_docx/30717500CC BY 4.0info:eu-repo/semantics/openAccessoai:figshare.com:article/307175002025-11-26T05:14:32Z |
| spellingShingle | Table 1_Immune checkpoint inhibitor therapy in advanced cancer: clinical association of irAEs type, inflammatory markers and efficacy.docx Mengying Qian (2541466) Genetic Immunology immune checkpoint inhibitors inflammatory biomarkers immune-related adverse events overall survival meta-analysis |
| status_str | publishedVersion |
| title | Table 1_Immune checkpoint inhibitor therapy in advanced cancer: clinical association of irAEs type, inflammatory markers and efficacy.docx |
| title_full | Table 1_Immune checkpoint inhibitor therapy in advanced cancer: clinical association of irAEs type, inflammatory markers and efficacy.docx |
| title_fullStr | Table 1_Immune checkpoint inhibitor therapy in advanced cancer: clinical association of irAEs type, inflammatory markers and efficacy.docx |
| title_full_unstemmed | Table 1_Immune checkpoint inhibitor therapy in advanced cancer: clinical association of irAEs type, inflammatory markers and efficacy.docx |
| title_short | Table 1_Immune checkpoint inhibitor therapy in advanced cancer: clinical association of irAEs type, inflammatory markers and efficacy.docx |
| title_sort | Table 1_Immune checkpoint inhibitor therapy in advanced cancer: clinical association of irAEs type, inflammatory markers and efficacy.docx |
| topic | Genetic Immunology immune checkpoint inhibitors inflammatory biomarkers immune-related adverse events overall survival meta-analysis |